1.
Elewski B, Menter A, Crowley J, Tyring S, Zhao Y, Lowry S, Rozzo S, Mendelsohn A, Parno J, Gordon K. Sustained and Improved Efficacy of Tildrakizumab from Week 28 to Week 52 in Treating Moderate-to-Severe Plaque Psoriasis. J of Skin [Internet]. 2018Feb.23 [cited 2024Jul.22];2(S1):S22. Available from: https://jofskin.org/index.php/skin/article/view/305